Notitia Biotechnologies Develops Revolutionary Foundation Guild Lbp for Patients With Diabetic Kidney Disease (DKD)

Notitia Biotechnologies Company has developed a ground-breaking live biotherapeutic product (LBP) for patients with early-stage and end-stage diabetic kidney disease (DKD) patients. The drug, NBT-BM306, combines the purified Foundation Guild bacteria and the tailored microbiome nutrition to support their growth in one convenient format.

Notitia is preparing the Investigational New Drug (IND) application to the FDA to start a Phase 1/2 combined clinical trial in Q1 2021. For more information regarding Notitia`s Foundation Guild Microbiome R&D Platform, please click here. For more information about the NBT-BM306`s development pipeline, please click here.